02 Dec 2021
· Regulatory information
Guard Therapeutics announces preliminary result of rights issue
The preliminary result of the rights issue that was announced on 20 October 2021 and where the subscription period ended on 29 November 2021 (the “Rights Issue”) in Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”), shows that the Rights Issue was subscribed to approximately 41 percent. The remaining approximately 59 percent of the Rights Issue is subscribed for by Rutger Arnhult, through M2 Asset Management AB, and Jan Ståhlberg in accordance with given declarations of intention to subscribe. As a result of the Rights Issue, Guard Therapeutics will receive proceeds amounting to approximately SEK 128 million before issue costs.
Read more
24 Nov 2021
· Regulatory information
Guard Therapeutics publishes supplementary prospectus
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”), and published on 10 November 2021 (the “Prospectus”).
Read more
22 Nov 2021
· Regulatory information
Guard Therapeutics reports positive results from preclinical studies
Guard Therapeutics today reports positive results from preclinical studies of the company’s investigational drug ROSgard in experimental animal models of sepsis. Two independent studies conducted at the Karolinska Institute show that ROSgard reduces the harmful effects that occur in both the liver and kidneys when these organs are exposed to a general inflammation and oxidative stress.
Read more
10 Nov 2021
· Regulatory information
Guard Therapeutics publishes prospectus due to upcoming rights issue
The Board of Directors of Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 20 October 2021 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”), which today has been approved and registered by the Swedish Financial Supervisory Authority.
Read more
20 Oct 2021
· Regulatory information
Guard Therapeutics carries out, subject to approval from the Extraordinary General Meeting, a directed new issue of approximately SEK 54 million and a rights issue of approximately SEK 128 million
Read more
20 Oct 2021
· Regulatory information
Guard Therapeutics intends to carry out a capital raise of approximately SEK 180 million
Read more
15 Sep 2021
· Regulatory information
Guard Therapeutics reports positive results from phase 1b study
Guard Therapeutics today presents positive results from a clinical phase 1b study of the potentially kidney-protecting biological investigational drug ROSgard in connection with open heart surgery. The study fulfilled its primary objective – to confirm ROSgard’s favourable safety and tolerability profile in the patient population for which treatment is initially intended. In addition, explorative analyses of several well-established biomarkers indicate that ROSgard potentially has the ability to protect kidney cells from injury associated with heart surgery. The company is now continuing its preparations for a comprehensive clinical phase 2 study.
Read more
01 Sep 2021
European Patent Office grants patent for Guard Therapeutics’ candidate ROSgard
Guard Therapeutics AB (publ.) announces that the European Patent Office (EPO) today has granted a patent for the company’s biological investigational drug ROSgard, both as a product and for its medical use. The patent provides protection in Europe until 2037.
Read more
17 Jun 2021
Last patient recruited to Guard Therapeutics’ phase 1b study of the investigational drug ROSgard
Guard Therapeutics announces today that all 12 patients have been included in the company’s clinical phase 1b study of ROSgard, which is being conducted in people undergoing open heart surgery who have additional risk factors for acute kidney injury. The study is being conducted at the University Hospital in Münster, Germany. Top-line results are expected to be presented in September 2021.
Read more
31 May 2021
Guard Therapeutics establishes a scientific committee with prominent international physicians and researchers in cardiothoracic surgery, intensive care and nephrology
Guard Therapeutics today announces that the company has established an external Scientific Advisory Committee (SAC) initially consisting of five global experts. The committee’s main task in the near future will be to contribute their expertise in the final design of the planned phase 2 study of the company’s investigational drug ROSgard in patients undergoing cardiac surgery.
Read more